Diagnosis and treatment options for nerve sheath tumors

References

• Pilavaki M, Chourmouzi D, Kiziridou A, Skordalaki A, Zarampoukas T, Drevelengas A. Imaging of peripheral nerve sheath tumors with pathologic correlation: pictorial review. Eur. J. Radiol. 52(3), 229–239 (2004).
   Google Scholar
• Moukarbel RV, Sabri AN. Current management of head and neck schwannomas. Curr. Opin. Otolaryngol. Head Neck Surg. 13(2), 117–122 (2005).
   PubMedGoogle Scholar
• Huang JH, Simon SL, Nagpal S, Nelson PT, Zager EL. Management of patients with schwannomatosis: report of six cases and review of the literature. Surg. Neurol.62(4), 353–361 (2004).
   PubMedGoogle Scholar
• Huang JH, Zaghloul K, Zager EL. Surgical management of brachial plexus region tumors. Surg. Neurol. 61(4), 372–378 (2004).
   PubMedGoogle Scholar
• Skovronsky DM, Oberholtzer JC. Pathologic classification of peripheral nerve tumors. Neurosurg. Clin. N. Am. 15(2), 157–166 (2004).
   PubMed Web of Science ®Google Scholar
• Ducatman BS, Scheithauer BW. Postirradiation neurofibrosarcoma. Cancer 51(6), 1028–1033 (1983).
   PubMed Web of Science ®Google Scholar
• Ducatman BS, Scheithauer BW, Piepgras DG, Reiman HM, Ilstrup DM. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer 57(10), 2006–2021 (1986).
   PubMed Web of Science ®Google Scholar
• Haraida S, Nerlich AG, Bise K, Wiest I, Schleicher E. Comparison of various basement membrane components in benign and malignant peripheral nerve tumours. Virchows Arch. A. Pathol. Anat. Histopathol. 421(4), 331–338 (1992).
   Google Scholar
• Nerlich AG, Haraida S, Wiest I. Basement membrane components as differential markers for mesenchymal tumors of various origin. Anticancer Res. 14(2B), 683–692 (1994).
   Google Scholar
• Perrin RG, Guha A. Malignant peripheral nerve sheath tumors. Neurosurg. Clin. N. Am.15(2), 203–216 (2004).
   Google Scholar
• Stark AM, Buhl R, Hugo HH, Mehdorn HM. Malignant peripheral nerve sheath tumours – eport of 8 cases and review of the literature. Acta Neurochir. (Wien) 143(4), 357–364 (2001).
   PubMed Web of Science ®Google Scholar
• Seymour-Dempsey K, Andrassy RJ. Neurofibromatosis: implications for the general surgeon. J. Am. Coll. Surg.195(4), 553–563 (2002).
   Google Scholar
• Gutmann DH, Aylsworth A, Carey JC et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 278(1), 51–57 (1997).
   PubMed Web of Science ®Google Scholar
• Riccardi VM. Von Recklinghausen neurofibromatosis. N. Engl. J. Med. 305(27), 1617–1627 (1981).
   PubMed Web of Science ®Google Scholar
• Gutmann DH. Recent insights into neurofibromatosis Type 1: clear genetic progress. Arch. Neurol. 55(6), 778–780 (1998).
   Google Scholar
• Wallace MR, Marchuk DA, Andersen LB et al. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science 249(4965), 181–186 (1990).
   PubMed Web of Science ®Google Scholar
• Parada LF. Neurofibromatosis Type 1. Biochim. Biophys. Acta. 1471(1), M13–M19 (2000).
   Google Scholar
• North K. Neurofibromatosis Type 1. Am J Med. Genet. 97(2), 119–127 (2000).
   Google Scholar
• Lynch TM, Gutmann DH. Neurofibromatosis 1. Neurol. Clin. 20(3), 841–865 (2002).
   PubMedGoogle Scholar
• Trofatter JA, MacCollin MM, Rutter JL et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 75(4), 826 (1993).
   PubMedGoogle Scholar
• Rouleau GA, Merel P, Lutchman M et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis Type 2. Nature 363(6429), 515–521 (1993).
   PubMed Web of Science ®Google Scholar
• Martuza RL, Eldridge R. Neurofibromatosis 2 (bilateral acoustic neurofibromatosis). N. Engl. J. Med. 318(11), 684–688 (1988).
   PubMed Web of Science ®Google Scholar
• Mulvihill JJ, Parry DM, Sherman JL, Pikus A, Kaiser-Kupfer MI, Eldridge R. NIH conference. Neurofibromatosis 1 (Recklinghausen disease) and neurofibromatosis 2 (bilateral acoustic neurofibromatosis). An update. Ann. Intern. Med.113(1), 39–52 (1990).
   PubMed Web of Science ®Google Scholar
• Evans DG, Sainio M, Baser ME. Neurofibromatosis Type 2. J. Med. Genet. 37(12), 897–904 (2000).
   PubMed Web of Science ®Google Scholar
• Jacoby LB, Jones D, Davis K et al. Molecular analysis of the NF2 tumor-suppressor gene in schwannomatosis. Am. J. Hum. Genet. 61(6), 1293–1302 (1997).
   PubMedGoogle Scholar
• MacCollin M, Woodfin W, Kronn D, Short MP. Schwannomatosis: a clinical and pathologic study. Neurology 46(4), 1072–1079 (1996).
   PubMed Web of Science ®Google Scholar
• Seppala MT, Sainio MA, Haltia MJ, Kinnunen JJ, Setala KH, Jaaskelainen JE. Multiple schwannomas: schwannomatosis or neurofibromatosis Type 2? J. Neurosurg. 89(1), 36–41 (1998).
   Google Scholar
• Purcell SM, Dixon SL. Schwannomatosis. An unusual variant of neurofibromatosis or a distinct clinical entity? Arch. Dermatol. 125(3), 390–393 (1989).
   PubMedGoogle Scholar
• Suh JS, Abenoza P, Galloway HR, Everson LI, Griffiths HJ. Peripheral (extracranial) nerve tumors: correlation of MR imaging and histologic findings. Radiology 183(2), 341–346 (1992).
   PubMed Web of Science ®Google Scholar
• Filler AG, Kliot M, Howe FA et al. Application of magnetic resonance neurography in the evaluation of patients with peripheral nerve pathology. J. Neurosurg. 85(2), 299–309 (1996).
   Google Scholar
• Maniker AH. Diagnostic steps, imaging, and electrophysiology. Neurosurg. Clin. N. Am. 15(2), 133–144 (2004).
   Google Scholar
• Artico M, Cervoni L, Wierzbicki V, D’Andrea V, Nucci F. Benign neural sheath tumours of major nerves: characteristics in 119 surgical cases. Acta Neurochir. (Wien) 139(12), 1108–1116 (1997).
   PubMedGoogle Scholar
• Hughes DG, Wilson DJ. Ultrasound appearances of peripheral nerve tumours. Br. J. Radiol. 59(706), 1041–1043 (1986).
   Google Scholar
• Martinoli C, Bianchi S, Derchi LE. Ultrasonography of peripheral nerves. Semin. Ultrasound CT MR. 21(3), 205–213 (2000).
   Google Scholar
• Huang JH, Samadani U, Zager EL. Brachial plexus region tumors: a review of their history, classification, surgical management, and outcomes. Neurosurgery Quarterly13(3), 151–161 (2003).
   Google Scholar
• Tiel R, Kline D. Peripheral nerve tumors: surgical principles, approaches, and techniques. Neurosurg. Clin. N. Am. 15(2), 167–175 (2004).
   Google Scholar
• Abaza MM, Makariou E, Armstrong M, Lalwani AK. Growth rate characteristics of acoustic neuromas associated with neurofibromatosis Type 2. Laryngoscope 106(6), 694–699 (1996).
   PubMedGoogle Scholar
• Mendenhall WM, Friedman WA, Amdur RJ, Antonelli PJ. Management of acoustic schwannoma. Am. J. Otolaryngol. 25(1), 38–47 (2004).
   PubMedGoogle Scholar
• Deen HG, Ebersold MJ, Harner SG et al. Conservative management of acoustic neuroma: an outcome study. Neurosurgery 39(2), 260–266 (1996).
   PubMed Web of Science ®Google Scholar
• Wiet RJ, Zappia JJ, Hecht CS, O’Connor CA. Conservative management of patients with small acoustic tumors. Laryngoscope 105(8), 795–800 (1995).
   PubMedGoogle Scholar
• Darrouzet V, Martel J, Enee V, Bebear JP, Guerin J. Vestibular schwannoma surgery outcomes: our multidisciplinary experience in 400 cases over 17 years. Laryngoscope 114(4), 681–688 (2004).
   PubMed Web of Science ®Google Scholar
• Skrivan J, Zverina E, Betka J, Kluh J, Kraus J. Our surgical experience with large vestibular schwannomas. Otolaryngol. Pol. 58(1), 69–72 (2004).
   Google Scholar
• Hasegawa T, Kida Y, Kobayashi T, Yoshimoto M, Mori Y, Yoshida J. Long-term outcomes in patients with vestibular schwannomas treated using gamma knife surgery: 10-year follow-up. J. Neurosurg. 102(1), 10–16 (2005).
   PubMed Web of Science ®Google Scholar
• Kaylie DM, McMenomey SO. Microsurgery vs. gamma knife radiosurgery for the treatment of vestibular schwannomas. Arch. Otolaryngol. Head Neck Surg. 129(8), 903–906 (2003).
   Google Scholar
• Litvack ZN, Noren G, Chougule PB, Zheng Z. Preservation of functional hearing after gamma knife surgery for vestibular schwannoma. Neurosurg. Focus 14(5), e3 (2003).
   PubMedGoogle Scholar
• Lunsford LD, Niranjan A, Flickinger JC, Maitz A, Kondziolka D. Radiosurgery of vestibular schwannomas: summary of experience in 829 cases. J. Neurosurg. 102, 195–199 (2005).
   PubMed Web of Science ®Google Scholar
• Kunisada T, Kawai A, Ozaki T, Sugihara S, Taguchi K, Inoue H. A clinical analysis of malignant schwannoma. Acta Med. Okayama 51(2), 87–92 (1997).
   Google Scholar
• Wanebo JE, Malik JM, VandenBerg SR, Wanebo HJ, Driesen N, Persing JA. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 28 cases. Cancer 71(4), 1247–1253 (1993).
   PubMed Web of Science ®Google Scholar
• Galanis E, Okuno SH, Nascimento AG et al. Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas. Gene Ther. 12(5), 437–445 (2005).
   PubMed Web of Science ®Google Scholar
• Kasper B, Lehnert T, Bernd L et al. High-dose chemotherapy with autologous peripheral blood stem cell transplantation for bone and soft-tissue sarcomas. Bone Marrow Transplant 34(1), 37–41 (2004).
   PubMed Web of Science ®Google Scholar
• Masui F, Yokoyama R, Soshi S, Beppu Y, Asanuma K, Fujii K. A malignant peripheral nerve-sheath tumour responding to chemotherapy. J. Bone Joint Surg. Br. 86(1), 113–115 (2004).
   Google Scholar
• Khanfir K, Alzieu L, Terrier P et al. Does adjuvant radiation therapy increase loco-regional control after optimal resection of soft-tissue sarcoma of the extremities? Eur. J. Cancer 39(13), 1872–1880 (2003).
   PubMed Web of Science ®Google Scholar
• Pollack A, Zagars GK, Goswitz MS, Pollock RA, Feig BW, Pisters PW. Preoperative vs. postoperative radiotherapy in the treatment of soft tissue sarcomas: a matter of presentation. Int. J. Radiat. Oncol. Biol. Phys. 42(3), 563–572 (1998).
   PubMed Web of Science ®Google Scholar
• Robinson MH, Keus RB, Shasha D, Harrison LB. Is pre-operative radiotherapy superior to postoperative radiotherapy in the treatment of soft tissue sarcoma? Eur. J. Cancer34(9), 1309–1316 (1998).
   Google Scholar
• Chung WY, Liu KD, Shiau CY et al. Gamma knife surgery for vestibular schwannoma: 10-year experience of 195 cases. J. Neurosurg.102, 87–96 (2005).
   PubMedGoogle Scholar
• Flickinger JC, Kondziolka D, Niranjan A, Lunsford LD. Results of acoustic neuroma radiosurgery: an analysis of 5 years’ experience using current methods. J. Neurosurg. 94(1), 1–6 (2001).
   PubMed Web of Science ®Google Scholar
• Kondziolka D, Lunsford LD, McLaughlin MR, Flickinger JC. Long-term outcomes after radiosurgery for acoustic neuromas. N. Engl. J. Med. 339(20), 1426–1433 (1998).
   PubMed Web of Science ®Google Scholar
• Jhanwar SC, Chen Q, Li FP, Brennan MF, Woodruff JM. Cytogenetic analysis of soft tissue sarcomas. Recurrent chromosome abnormalities in malignant peripheral nerve sheath tumors (MPNST). Cancer Genet. Cytogenet. 78(2), 138–144 (1994).
   PubMed Web of Science ®Google Scholar
• Kourea HP, Cordon-Cardo C, Dudas M, Leung D, Woodruff JM. Expression of p27(kip) and other cell cycle regulators in malignant peripheral nerve sheath tumors and neurofibromas: the emerging role of p27(kip) in malignant transformation of neurofibromas. Am. J. Pathol. 155(6), 1885–1891 (1999).
   PubMed Web of Science ®Google Scholar
• Nielsen GP, Stemmer-Rachamimov AO, Ino Y, Moller MB, Rosenberg AE, Louis DN. Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation. Am. J. Pathol. 155(6), 1879–1884 (1999).
   PubMed Web of Science ®Google Scholar
• Angelov L, Salhia B, Roncari L, McMahon G, Guha A. Inhibition of angiogenesis by blocking activation of the vascular endothelial growth factor receptor 2 leads to decreased growth of neurogenic sarcomas. Cancer Res. 59(21), 5536–5541 (1999).
   PubMed Web of Science ®Google Scholar
• Perosio PM, Brooks JJ. Expression of growth factors and growth factor receptors in soft tissue tumors. Implications for the autocrine hypothesis. Lab. Invest. 60(2), 245–253 (1989).
   Google Scholar
• Hirota S, Nomura S, Asada H, Ito A, Morii E, Kitamura Y. Possible involvement of c-kit receptor and its ligand in increase of mast cells in neurofibroma tissues. Arch. Pathol. Lab. Med. 117(10), 996–999 (1993).
   PubMed Web of Science ®Google Scholar
• Arbiser JL, Flynn E, Barnhill RL. Analysis of vascularity of human neurofibromas. J. Am. Acad. Dermatol. 38(6), 950–954 (1998).
   Google Scholar
• DeClue JE, Heffelfinger S, Benvenuto G et al. Epidermal growth factor receptor expression in neurofibromatosis Type 1-related tumors and NF1 animal models. J. Clin. Invest. 105(9), 1233–1241 (2000).
   PubMed Web of Science ®Google Scholar
• Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Arch. Neurol. 45(5), 575–578 (1988).
   PubMed Web of Science ®Google Scholar